Legal Status
Legal Status
Rule
Oral Dosage Form New Animal Drugs; Spectinomycin Dihydrochloride Oral Solution
A Rule by the Food and Drug Administration on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 08/30/2004
- Agencies:
- Food and Drug Administration
- Dates:
- This rule is effective August 30, 2004.
- Effective Date:
- 08/30/2004
- Document Type:
- Rule
- Document Citation:
- 69 FR 52815
- Page:
- 52815-52816 (2 pages)
- CFR:
- 21 CFR 520
- Document Number:
- 04-19655
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
- This feature is not available for this document.
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/04-19655 https://www.federalregister.gov/d/04-19655
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for the oral use of spectinomycin dihydrochloride pentahydrate oral solution in pigs under 4 weeks of age for the treatment and control of infectious bacterial enteritis.
DATES:
This rule is effective August 30, 2004.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Lonnie W. Luther, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301-827-8549, e-mail: lonnie.luther@fda.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed ANADA 200-364 that provides for oral use of SPECMED (spectinomycin dihydrochloride pentahydrate) Scour-Chek in pigs under 4 weeks of age for the treatment and control of infectious bacterial enteritis (white scours) associated with Escherichia coli. Cross Vetpharm Group Ltd.'s SPECMED Scour-Chek is approved as a generic copy of Phoenix Scientific, Inc.'s SPECTAM Scour Halt, approved under NADA 033-157. The ANADA is approved as of July 29, 2004, and the regulations are amended by removing 21 CFR 520.2122 and by adding 21 CFR 520.2123c to reflect the approval. The basis of approval is discussed in the freedom of information summary.
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of SubjectsList of Subject in 21 CFR Part 520
- Animal drugs
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:
End Amendment Part Start PartPART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 520 continues to read as follows:
End Amendment Part Start AuthorityAuthority: 21 U.S.C. 360b.
End Authority2. Section 520.2122 is removed.
End Amendment Part Start Amendment Part3. Section 520.2123c is added to read as follows:
End Amendment Part(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) spectinomycin activity.
(b) Sponsors. See Nos. 000856, 059130, and 061623 in § 510.600(c) of this chapter.
(c) Conditions of use in swine—(1) Amount. Administer 5 mg per pound (lb) of body weight orally twice daily for 3 to 5 days.
Start Printed Page 52816(2) Indications for use. For the treatment and control of infectious bacterial enteritis (white scours) associated with E. coli in pigs under 4 weeks of age.
(3) Limitations. Do not administer to pigs over 15 lb of body weight or over 4 weeks of age. Do not administer within 21 days of slaughter.
Start SignatureDated: August 17, 2004.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 04-19655 Filed 8-27-04; 8:45 am]
BILLING CODE 4160-01-S